Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Park Hotels & Resorts Inc. Common Stock (PK) Price & Performance

Inovio Pharmaceuticals IncTrade
Park Hotels & Resorts Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Park Hotels & Resorts Inc. Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.96 (market cap $103.19M), while Park Hotels & Resorts Inc. Common Stock trades at $15.12 (market cap $3.14B). The key difference: Park Hotels & Resorts Inc. Common Stock is far larger — about 30.4× Inovio Pharmaceuticals Inc's market cap, and Park Hotels & Resorts Inc. Common Stock pays a 6.41% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Park Hotels & Resorts Inc. Common Stock for 0 Days on average.

INOPK
Market Cap
$103.19M$3.14B
Volume
8,461,5803,553,985
Sector
HealthReal Estate
52-Week High
$2.60$16.17
52-Week Low
$0.66$9.84
Typical Hold Time
43 Days0 Days
Enterprise Value
$74.52M$6.98B
Dividend Yield
—6.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.

The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.

Park Hotels & Resorts Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
97% Buy3% Sell
Avg holding period · 43 Days
PK
100% Buy0% Sell
Avg holding period · 0 Days

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Park Hotels & Resorts Inc. Common Stock

Park Hotels & Resorts Inc. is a US lodging REIT, spun off from Hilton Worldwide in 2017, that owns a portfolio of premium-branded hotels and resorts in major urban, resort, and convention markets.

Read more on PK →